摘要
目的比较甘精胰岛素与格列本脲对初诊2型糖尿病(T2DM)的疗效及安全性。方法将60例T2DM患者随机分为3组,每组20例。A组给予甘精胰岛素联合二甲双胍,B组给予格列本脲联合二甲双胍,C组给予精蛋白生物合成人胰岛素注射液(预混30R)。比较3组患者治疗前后空腹血糖(FPG)、餐后2 h血糖(2hPG)、糖化血红蛋白(HbAlc)、餐后C肽水平变化,以及A、B组低血糖发生率。结果 A组各指标改善情况均显著优于B、C组,B组各指标改善情况有优于C组的趋势,但除HbAlc外,其余指标间差异均无统计学意义。A组前6周及后6周低血糖发生率均有低于B组的趋势,但差异无统计学意义。结论甘精胰岛素联合二甲双胍治疗T2DM,可以显著降低患者血糖,改善糖代谢,且低血糖发生率较低,安全性高,优于格列本脲联合二甲双胍,值得临床推广。
Objective To compare the therapeutic effects and safety of insulin glargine and glimepiride in the treatment of newly diagnosed type 2 diabetes mellitus （T2DM）. Methods Sixty T2DM patients were randomly divided into 3 groups, 20 cases in each group. Group A was adminis- tered insulin glargine combined with metformin, group B glimepiride combined with metformin and group C Isophane Protamine Biosynthetic Human Insulin Injection （premix 30R）. Before and after treatment, the levels of fasting plasma glucose （FPG）, 2 h postprandial plasma glucose （2 hPG）, glycosylated hemoglobin （HbAlc） and postprandial C peptide after meals in the patients of 3 groups as well as hypoglycemia incidences of groups A and B were compared. Results The improved condition of each index in group A was markedly superior to those in groups B and C. The improved conditions of group B showed the tendency of preceding group C, but there was no statistical signifi- cance among each indexes except for HbAlc. The hypoglycemia incidences of group A in both previous and later 6 weeks showed the tendency of being inferior to group B, but the difference showed no statistical significance. Conclusion Insulin glargine combined with metformin in the treatment of T2DM, can significantly reduce the blood sugar and ameliorate glycometabolism, with a low inci- dence of hypoglycemia, high safety and superior to glimepiride combined with metformin, so it is worthy of clinical promotion.
出处
《实用临床医药杂志》
CAS
2013年第5期96-98,共3页
Journal of Clinical Medicine in Practice
基金
中国高校医学期刊临床专项资金(11320033)
